Analysis of Prices of Six Drug Classes for Cancer for U.S Including Platinum Drugs, Hormonal Agents, Antimetabolites and Monoclonal Antibodies.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43162) has announced the addition of Cancer TherapiesCoIs the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Always the Most Expensive Market? to their offering. The cost of innovative cancer drugs is an increasingly controversial issue. Strict price controls in many countries limit the prices that manufacturers can charge for medicines, whereas the United States' lenient drug pricing system Noun 1. pricing system - a system for setting prices on goods or services system - a procedure or process for obtaining an objective; "they had to devise a system that did not depend on cooperation" allows manufacturers much greater latitude to determine launch prices. However, pharmaceutical companies in all countries will need to adapt to a changing pricing environment for oncology drugs. Get the Answers You Need to Shape Your Strategy Concern is growing over the rising costs of cancer therapies, particularly in the United States, which has the highest drug prices overall. Have drug manufactures responded to this growing concern? Is government intervention necessary to regulate prices? Historically, the European hospital sector allowed free pricing of drugs, even in the most heavily regulated markets. But there is a growing trend to control hospital spending on medicines. What pricing controls are being proposed and how will they affect drug pricing in European markets? Drugs typically do not reach the Japanese market until several years after their launch in the other major pharmaceutical markets. However, Japan recently initiated measures to accelerate the launch of innovative cancer therapies. How will these measures affect future drug pricing and pricing controls in Japan? Scope National pricing trends: United States, France, Germany, Italy, Spain, United Kingdom, Japan Analysis of prices of six drug classes: platinum drugs, hormonal agents, taxanes, antimetabolites, monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). , and small-molecule tyrosine kinase inhibitors Outlook and implications for manufacturers: how these trends impact drug manufactures in each market under study Products Mentioned: * Alemtuzumab * Anastrozole * Bevacizumab * Bicalutamide * Capecitabine * Carboplatin * Cetuximab * Cisplatin cisplatin /cis·plat·in/ (sis´plat-in) DDP; a platinum coordination complex capable of producing inter- and intrastrand DNA crosslinks; used as an antineoplastic. cis·plat·in n. * Docetaxel * Erlotinib * Gefi tinib * Gemcitabine * Goserelin goserelin /go·se·rel·in/ (go´se-rel?in) a synthetic gonadotropin-releasing hormone; on prolonged administration it suppresses release of gonadotropins and is used as the acetate salt to treat breast and prostate carcinomas and * Imatinib * Leuprolide * Oxaliplatin * Paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); * Paclitaxel (modified) * Panitumumab * Rituximab * Trastuzumab The Companies mentioned inside this report include: * Abraxis Bioscience * Amgen * AstraZeneca * Berlex Labs * Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec * Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were * Eli Lilly Eli Lilly can refer to:
* Genentech * ImClone Systems * Merck KGaA * Novartis * Roche * Sanofi -Aventis * Schering AG * TAP Pharmaceutical Products For more information visit http://www.researchandmarkets.com/reports/c43162 Source: Decision Resources |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion